Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TLR8 | Q9NR97 | 8/20 | 0.65 |
| ▸ | NUDT1 | P36639 | 1/20 | 0.58 |
| ▸ | DNM2 | P50570 | 7/20 | 0.48 |
| ▸ | HRH4 | Q9H3N8 | 1/20 | 0.43 |
| ▸ | TLR7 | Q9NYK1 | 4/20 | 0.43 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.42 |
| ▸ | LMNA | P02545 | 1/20 | 0.42 |
| ▸ | TP53 | P04637 | 1/20 | 0.42 |
| ▸ | TSHR | P16473 | 1/20 | 0.42 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.42 |
| ▸ | HTT | P42858 | 1/20 | 0.42 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.42 |
| ▸ | ESR1 | P03372 | 1/20 | 0.41 |
| ▸ | ESR2 | Q92731 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7164892 | 0.90 | NUDT1 (0.62) | TLR8NUDT1DNM2HRH4ESR1 | |
| SCHEMBL9651803 | 0.86 | TLR8 (0.63) | TLR8NUDT1HRH4TLR7ALDH1A1 | |
| SCHEMBL9182270 | 0.83 | NUDT1 (0.66) | TLR8NUDT1DNM2HRH4SMN1; SMN2 | |
| SCHEMBL16543306 | 0.83 | DNM2 (0.52) | TLR8NUDT1DNM2ALDH1A1LMNA | |
| SCHEMBL20434279 | 0.80 | TLR8 (0.73) | TLR8HRH4TLR7ALDH1A1LMNA | |
| SCHEMBL20434306 | 0.79 | TLR8 (1.00) | TLR8DNM2TLR7ALDH1A1LMNA | |
| SCHEMBL8600881 | 0.78 | TLR8 (0.69) | TLR8HRH4TLR7ALDH1A1LMNA | |
| SCHEMBL20434304 | 0.75 | TLR8 (0.65) | TLR8TLR7ALDH1A1LMNATP53 | |
| SCHEMBL20109484 | 0.74 | NUDT1 (1.00) | NUDT1 | |
| SCHEMBL2849398 | 0.74 | TLR8 (0.90) | TLR8DNM2HRH4TLR7ALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20020103216-A1 | Administering topically a tyrosinase activity-stimulating amount of a 6-substituted pyrimidine 3-oxide | PRUCHE FRANCIS (FR) | 2002-08-01 | — | — | US | claimed |
| US-6380263-B1 | ADMINISTERING TO HUMAN EFFECTIVE TYROSINASE ACTIVITY-STIMULATING AMOUNT OF AT LEAST ONE 6-SUBSTITUTED PYRIMIDINE 3-OXIDE COMPOUND FOR PROMOTING PIGMENTATION OF THE SKIN AND/OR HAIR | SOCIETE L'OREAL (FR) | 2002-04-30 | — | — | US | claimed |
| US-9480663-B2 | Biguanide compositions and methods of treating metabolic disorders | ELCELYX THERAPEUTICS, INC. (US) | 2016-11-01 | — | — | US | disclosed |
| US-9480663-B2 | Biguanide compositions and methods of treating metabolic disorders | ELCELYX THERAPEUTICS, INC. (US) | 2016-11-01 | — | — | US | disclosed |
| US-20150064223-A1 | Biguanide Compositions and Methods of Treating Metabolic Disorders | ELCELYX THERAPEUTICS, INC. (US) | 2015-03-05 | — | — | US | disclosed |
| US-20150064223-A1 | Biguanide Compositions and Methods of Treating Metabolic Disorders | ELCELYX THERAPEUTICS, INC. (US) | 2015-03-05 | — | — | US | disclosed |
| EP-0519819-B1 | Composition for use to reduce hair loss and to induce and stimulate its growth, containing derivatives of 2,4,6-triaminopyrimidin-N-oxide and the new derivatives of 2,4,6-triaminopyrimidin-N-oxide | OREAL (FR) | 1995-07-19 | — | — | EP | disclosed |
| EP-0519819-A1 | Composition for use to reduce hair loss and to induce and stimulate its growth, containing derivatives of 2,4,6-triaminopyrimidin-N-oxide and the new derivatives of 2,4,6-triaminopyrimidin-N-oxide | L'OREAL (FR) | 1992-12-23 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20150064223-A1 | Biguanide Compositions and Methods of Treating Metabolic Disorders | SLC5A2, SLC5A1, GPR119 | TLR8 2317/4885NUDT1 222/4885DNM2 1512/4885 |
| US-20020103216-A1 | Administering topically a tyrosinase activity-stimulating amount of a 6-substituted pyrimidine 3-oxide | TYR, TH, MC1R | TLR8 3499/4885NUDT1 38/4885DNM2 3991/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.